Booster Dose of Meningococcal ACWY Vaccine Supported by AAFP

With the increased risk of meningococcal disease in adolescent patients, full vaccination against the disease in key to reducing incidence. In January 2011, the ACIP recommended that a second (booster) dose of MCV4 be given at age 16 in order to enhance protection during the period of greatest vulnerability to meningococcal – 16 to 21 years of age.

Unfortunately, more than four years after this recommendation was published, the 2-dose coverage rate for MCV4 in 17-year-olds is only 28.5% The AAFP has joined five other prominent national medical associations in urging providers to take advantage of opportunities to vaccinate during all patient encounters, including well visits, camp and sports physicals, visits for acute or chronic illness, and visits for other recommended immunizations, including a second dose of ACWY.

To learn more about the booster recommendation, including what patients it’s aimed at, visit